| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,147 | 0,166 | 13:04 | |
| 0,147 | 0,166 | 06.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PRESENTS LATE-BREAKING DATA FROM ONGOING PHASE 2 ENSURE STUDY AT AASLD 2025 | 1 | HKEx | ||
| 07.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PUBLICATION OF PHASE 2 ENSURE STUDY RESULTS IN NATURE MEDICINE | - | HKEx | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 31.10.25 | BRII-B (02137): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 28.10.25 | BRII-B (02137): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | 1 | HKEx | ||
| 27.10.25 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.09.25 | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 18.09.25 | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 18.09.25 | BRII-B (02137): 2025 INTERIM REPORT | - | HKEx | ||
| 17.09.25 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 27.08.25 | BRII-B (02137): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2024 | 3 | HKEx | ||
| 25.08.25 | Leerink Partners raises Brii Biosciences stock price target to HK$2.00 on HBV data | 2 | Investing.com | ||
| 25.08.25 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 21.08.25 | Brii Biosciences reports 1H results | 1 | Seeking Alpha | ||
| 21.08.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | 133 | PR Newswire | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic... ► Artikel lesen | |
| 21.08.25 | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 11.08.25 | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 30.03.25 | Brii Biosciences Limited: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | 146 | PR Newswire | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and... ► Artikel lesen | |
| 21.03.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results | 645 | PR Newswire | Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Data... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 164,25 | +3,79 % | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| ILLUMINA | 101,04 | -0,18 % | Illumina-Aktie -10%: Kann man hier günstig einsteigen? | Mit einem Kursverlust von -10% war die Illumina-Aktie am Freitag der große Verlierer im S&P 500. Der Hersteller von Gensequenzierungsmaschinen setzte damit seinen Abwärtstrend der letzten Tage fort.... ► Artikel lesen | |
| NANOREPRO | 1,535 | +2,68 % | NanoRepro ordnet Aufsichtsrat nach außerordentlicher HV neu | Die Aktionäre der NanoRepro AG haben auf der außerordentlichen Hauptversammlung vom 16. Januar 2026 den Aufsichtsrat neu zusammengesetzt. Neu gewählt wurden Gunter Heneis, Michael Herrmann und Konstantin... ► Artikel lesen | |
| BRAIN BIOTECH | 2,240 | +0,90 % | Brain Biotech: Kursziel der Aktie wird gestutzt | Die Analysten der Deutschen Bank bezeichnen die jüngsten Zahlen von Brain Biotech als Enttäuschung. 2024/2025 sinkt der Umsatz von 54,6 Millionen Euro auf 49,6 Millionen Euro. Für das neue Geschäftsjahr... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,387 | +2,38 % | BioNxt sichert sich innovative Chaperon-Technologie zur Verbesserung der oralen Dünnfilm-Wirkstoffverabreichung | VANCOUVER, BC / ACCESS Newswire /
5. Februar 2026 - BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT), ein biowissenschaftliches
Innovationsunternehmen... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem downgraded to NEX | ||
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,150 | +1,77 % | Burcon NutraScience Corporation: Burcon Announces Details on Special Meeting of Shareholders and Amendment to Outstanding Warrants | Vancouver, British Columbia--(Newsfile Corp. - February 4, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| TME PHARMA | 0,065 | 0,00 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| CYTODYN | 0,195 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| IMMUNIC | 0,511 | -1,73 % | EQS-News: Immunic AG: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Conference/Study results
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,114 | -1,45 % | Iovance Biotherapeutics, Inc.: Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma | SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,920 | +7,39 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen |